Vaccination to promote the health equilibrium and diseases prevention
The swine genetic progress enables farmers to highly increase their piglets’ production. The size of the litters has increased but there are big differences in term of weight and size of the piglets inside a litter.
Weak piglets will not grow as fast and as much as big ones, even though belonging they have the same mother.
Farmers want to ensure the best possible conditions for both animal welfare and productivity.
During an animal's life or during the production cycle, there are still periods when oxidative stress is particularly intense. In such cases, farmers must provide the animals with trace elements.
In Korea, the PCV2 vaccination is made in almost 100% of the farms. In spite of this vaccination, the PCV2 still causes important economic losses due to the lower weight daily gain and delayed time tomarket.
The main genotype which has been identified in the PCV2 positive tested cases by the Pr Kim Won 11 team is the genotype d, involved in about 90% of positive cases.
Thanks to laboratory and field studies, Pr Kim Won II thinks that there is possibly an interaction between maternally derived antibodies and piglets’ vaccination, based on seroconversion data and subsequent pigs protection.
Since the discovery of PCV2 in 1998, researchers tried to characterize PCV2 and found out that there were several genotypes.
Today, researchers found out at least eight different PCV2 genotype around the globe. Three of these genotypes have been particularly important in the pig population: PCV2a, PCV2b and PCV2d, the latest being now the most prevalent worldwide. The virulence of the PCV2 can vary from a strain to another in the same genotype, but there is not significant difference of virulence between the different genotypes.
The majority of PCV2 vaccines have been developed based on PCV2a genotype and later confirmed as cross protecting against other genotypes. However homologous genotype between vaccine and field strain would be preferable.
Suigen PCV2 is the first global vaccine developed from a PCV2d strain which is the current predominant PCV2 genotype. It is characterized by its ready to use whole inactivated virus formulation, a high titer and a double emulsion (water in oil in water) insuring excellent tolerance and proper antigens release.
Suigen PCV2 has been tested in several Asian countries according to controlled and field conditions, showing induction of specific humoral and cell mediated immunity, reduction of viral burden and improvement of performances by comparison to non vaccinated animals. Moreover tolerance was excellent and both laboratory and field criteria were equivalent with reference vaccines.
PCV2d is now the predominant genotype in Korea and has been previously isolated in PCVAD cases in vaccinated herds.
Objective of these studies were to assess safety and efficacy of a newly developed PCV2 vaccine based on the PCV2d genotype now predominant in many regions.
Nulla sollicitudin placerat mi, nec commodo risus convallis in.
-resize1680x1119-crop1457x414.jpg)
